I think I have posted this MSS-eligible immunotherapy trial before but I noticed today that it has finally opened trial sites in the United States (previously it was Europe only) - so I wanted to repost. Your tumor needs to be CEA-positive. It combines a targeted form of IL-2 "RO6895882" (to activate the immune system in the vicinity of tumor) along with a PDL1 immunotherapy. It has trial locations in NYC and CT. I believe there can be a disconnect between CEA-expression on the tumor itself and what they measure floating in the blood stream - so I would not discard this trial possibility based upon bloodstream CEA results before talking to a MD at the trial. https://clinicaltrials.gov/ct2/show/NCT ... 673&rank=1
-DK